Merck & Co., Inc. (MRK)

Over the past six months, Merck's stock has experienced notable movements, with a closing share price of $119.75 as of February 5, 2026. Key events include the company's fourth-quarter 2025 earnings report, which surpassed analyst estimates but was followed by a cautious financial outlook for 2026. Acquisitions of Verona Pharma and Cidara Therapeutics, along with a license agreement with Hengrui Pharma, also impacted the stock. Insider selling by several executives occurred in early February 2026.

Merck & Co., Inc. experiences some demand seasonality, particularly due to the resetting of Medicare deductibles affecting products like Ohtuvayre. In its animal health business, companion animal sales remained flat, partly attributed to a reduction in vet visits, which can also exhibit seasonal patterns. The pneumococcal vaccine Cefaxib sales were supported by stronger U.S. seasonal immunization activity.

Merck & Co., Inc. is a global biopharmaceutical company involved in the discovery, development, manufacturing, and marketing of prescription medicines, vaccines, biologic therapies, and animal health products, emphasizing areas like oncology, vaccines, infectious diseases, and therapies for metabolic and chronic conditions. Key products include Keytruda and Gardasil, along with Winrevair, Ohtuvayre, and a range of veterinary medicines and vaccines. The company's net sales are primarily from pharmaceutical products, followed by vaccines and animal health products.

Merck & Co., Inc. has a substantial global presence, operating under the name MSD outside the United States and Canada. Net sales are distributed across the United States, Europe/Middle East/Africa, China, Latin America, Japan, Asia/Pacific, and other regions. The company operates in seven regions: United States; Europe, Middle East and Africa; China; Latin America; Japan; Asia Pacific (other than China and Japan); and Other.

Merck's brand reputation has been characterized by its commitment to scientific excellence, innovation, and efforts to improve global health. However, a class-action lawsuit alleging false statements regarding revenue outlook and Gardasil vaccine growth has impacted its reputation. A trademark dispute with Merck KGaA regarding the use of the "Merck" name outside the U.S. and Canada also saw a development.

Merck & Co., Inc. has a significant institutional ownership base, with major holders including Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Institutional investors collectively own approximately 73% of Merck & Co.'s shares. Individual investors and insiders own about 27% of the company, with insiders holding only 0.13% of the stock.